Crystal Structures of Clinically Relevant Lys103Asn/Tyr181Cys Double Mutant HIV-1 Reverse Transcriptase in Complexes with ATP and Non-nucleoside Inhibitor HBY 097

Journal of Molecular Biology

Volumn 365, Issue 1, 2007, Pages 77-89

  Das, Kalyan ^a   Sarafianos, Stefan G ^a   Clark Jr , Arthur D ^a   Boyer, Paul L ^b   Hughes, Stephen H ^b   Arnold, Eddy ^a  

^a RUTGERS UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

conformational flexibility; drug design; drug resistance; polymerase

Indexed keywords

ADENOSINE TRIPHOSPHATE; ASPARTIC ACID; MANGANESE; RNA DIRECTED DNA POLYMERASE; TALVIRALINE; THIOL DERIVATIVE;

ARTICLE; CRYSTAL STRUCTURE; DRUG POTENCY; HYDROGEN BOND; METAL BINDING; MUTATION; PRIORITY JOURNAL; PROTEIN BINDING;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33751529192     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2006.08.097     Document Type: Article

References (62)

1. Staszewski S., Morales-Ramirez J., Tashima K.T., Rachlis A., Skiest D., Stanford J., et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New Engl. J. Med. 341 (1999) 1865-1873
2. Clumeck N., and De Wit S. Update on highly active antiretroviral therapy: progress and strategies. Biomed. Pharmacother. 54 (2000) 7-12
3. Rousseau M.N., Vergne L., Montes B., Peeters M., Reynes J., Delaporte E., and Segondy M. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J. Acquir. Immun. Defic. Syndr. 26 (2001) 36-43
4. Salomon H., Wainberg M.A., Brenner B., Quan Y., Rouleau D., Cote P., et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 14 (2000) F17-F23
5. O'Brien W.A. Resistance against reverse transcriptase inhibitors. Clin. Infect. Dis. 30 (2000) S185-S192
6. Sarafianos S.G., Das K., Hughes S.H., and Arnold E. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr. Opin. Struct. Biol. 14 (2004) 716-730
7. De Clercq E. In search of a selective antiviral chemotherapy. Clin. Microbiol. Rev. 10 (1997) 674-693
8. De Clercq E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaco 54 (1999) 26-45
9. Weidle P.J., Lichtenstein K.A., Moorman A.C., Von Bargen J.C., Greenberg K.S., Palella Jr. F.J., and Holmberg S.D. Factors associated with the successful modification of antiretroviral therapy. HIV Outpatient Study Investigators. AIDS 14 (2000) 491-497
10. Schinazi R.F., Mead J.R., and Feorino P.M. Insights into HIV chemotherapy. AIDS Res. Hum. Retroviruses 8 (1992) 963-990
11. Shulman N.S., Zolopa A.R., Passaro D.J., Murlidharan U., Israelski D.M., Brosgart C.L., et al. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. J. Acquir. Immune Defic. Syndr. 23 (2000) 221-226
12. Das K., Ding J., Hsiou Y., Clark Jr. A.D., Moereels H., Koymans L., et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 264 (1996) 1085-1100
13. Hsiou Y., Das K., Ding J., Clark Jr. A.D., Kleim J.P., Rosner M., et al. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J. Mol. Biol. 284 (1998) 313-323
14. Ren J., Milton J., Weaver K.L., Short S.A., Stuart D.I., and Stammers D.K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Struct. Fold. Des. 8 (2000) 1089-1094
15. Hsiou Y., Ding J., Das K., Clark Jr. A.D., Boyer P.L., Lewi P., et al. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J. Mol. Biol. 309 (2001) 437-445
16. Lindberg J., Sigurdsson S., Lowgren S., Andersson H.O., Sahlberg C., Noreen R., et al. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur. J. Biochem. 269 (2002) 1670-1677
17. Ren J., Nichols C.E., Chamberlain P.P., Weaver K.L., Short S.A., and Stammers D.K. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J. Mol. Biol. 336 (2004) 569-578
18. Cheung P.K., Wynhoven B., and Harrigan P.R. 2004: which HIV-1 drug resistance mutations are common in clinical practice?. AIDS Rev. 6 (2004) 107-116
19. Jourdain G., Ngo-Giang-Huong N., Le Coeur S., Bowonwatanuwong C., Kantipong P., Leechanachai P., et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. New Engl. J. Med. 351 (2004) 229-240
20. Demeter L.M., Meehan P.M., Morse G., Gerondelis P., Dexter A., Berrios L., et al. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J. Acquir. Immun. Defic. Syndr. Hum. Retrovirol. 14 (1997) 136-144
21. Casado J.L., Hertogs K., Ruiz L., Dronda F., Van Cauwenberge A., Arno A., et al. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS 14 (2000) F1-F7
22. Torti C., Pozniak A., Nelson M., Hertogs K., and Gazzard B.G. Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors. J. Antimicrob. Chemother. 48 (2001) 113-116
23. Clotet B. Efavirenz: resistance and cross-resistance. Int. J. Clin. Pract. Suppl. 103 (1999) 21-25
24. Bacheler L.T., Anton E.D., Kudish P., Baker D., Bunville J., Krakowski K., et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 44 (2000) 2475-2484
25. Demeter L.M., Shafer R.W., Meehan P.M., Holden-Wiltse J., Fischl M.A., Freimuth W.W., et al. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob. Agents Chemother. 44 (2000) 794-797
26. Janssen P.A., Lewi P.J., Arnold E., Daeyaert F., de Jonge M., Heeres J., et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile (R278474, Rilpivirine). J. Med. Chem. 48 (2005) 1901-1909
27. Das K., Lewi P.J., Hughes S.H., and Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol. 88 (2005) 209-231
28. Kleim J.P., Bender R., Kirsch R., Meichsner C., Paessens A., Rosner M., et al. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 39 (1995) 2253-2257
29. Balzarini J., Pelemans H., Riess G., Roesner M., Winkler I., De Clercq E., and Kleim J.P. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2′,3′-dideoxy-3′-thiacytidine (lamivudine). Biochem. Pharmacol. 55 (1998) 617-625
30. Rodgers D.W., Gamblin S.J., Harris B.A., Ray S., Culp J.S., Hellmig B., et al. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 92 (1995) 1222-1226
31. Hsiou Y., Ding J., Das K., Clark Jr. A.D., Hughes S.H., and Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 4 (1996) 853-860
32. Udier-Blagovic M., Watkins E.K., Tirado-Rives J., and Jorgensen W.L. Activity predictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase. Bioorg. Med. Chem. Letters 13 (2003) 3337-3340
33. Das K., Clark Jr. A.D., Lewi P.J., Heeres J., de Jonge M.R., et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-rresistant HIV-1 variants. J. Med. Chem. 47 (2004) 2550-2560
34. Kleim J.P., Winkler I., Rosner M., Kirsch R., Rubsamen-Waigmann H., Paessens A., and Riess G. In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097. Virology 231 (1997) 112-118
35. Arion D., Kaushik N., McS. Cormick G., and Borkow M.A. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37 (1998) 15908-15917
36. Meyer P.R., Matsuura S.E., So A.G., and Scott W.A. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc. Natl Acad. Sci. USA 95 (1998) 13471-13476
37. Boyer P.L., Sarafianos S.G., Arnold E., and Hughes S.H. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75 (2001) 4832-4842
38. Huang H., Chopra R., Verdine G.L., and Harrison S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282 (1998) 1669-1675
39. Tuske S., Sarafianos S.G., Clark Jr. A.D., Ding J., Naeger L.K., White K.L., et al. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nature Struct. Mol. Biol. 11 (2004) 469-474
40. Ding J., Das K., Hsiou Y., Sarafianos S.G., Clark Jr. A.D., Jacobo-Molina A., et al. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution. J. Mol. Biol. 284 (1998) 1095-1111
41. Sawaya M.R., Prasad R., Wilson S.H., Kraut J., and Pelletier H. Crystal structures of human DNA polymerase beta complexed with gapped and nicked DNA: evidence for an induced fit mechanism. Biochemistry 36 (1997) 11205-11215
42. Doublie S., and Ellenberger T. The mechanism of action of T7 DNA polymerase. Curr. Opin. Struct. Biol. 8 (1998) 704-712
43. Li Y., Korolev S., and Waksman G. Crystal structures of open and closed forms of binary and ternary complexes of the large fragment of Thermus aquaticus DNA polymerase I: structural basis for nucleotide incorporation. EMBO J. 17 (1998) 7514-7525
44. Sarafianos S.G., Das K., Ding J., Boyer P.L., Hughes S.H., and Arnold E. Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem. Biol. 6 (1999) R137-R146
45. Steitz T.A. DNA polymerases: structural diversity and common mechanisms. J. Biol. Chem. 274 (1999) 17395-17398
46. Johnson S.J., Taylor J.S., and Beese L.S. Processive DNA synthesis observed in a polymerase crystal suggests a mechanism for the prevention of frameshift mutations. Proc. Natl Acad. Sci. USA 100 (2003) 3895-3900
47. Bibillo A., Lener D., Klarmann G.J., and Le Grice S.F. Functional roles of carboxylate residues comprising the DNA polymerase active site triad of Ty3 reverse transcriptase. Nucl. Acids Res. 33 (2005) 171-181
48. Sarafianos S.G., Clark Jr. A.D., Das K., Tuske S., Birktoft J.J., Ilankumaran P., et al. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 21 (2002) 6614-6624
49. Beese L.S., and Steitz T.A. Structural basis for the 3′-5′ exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism. EMBO J. 10 (1991) 25-33
50. Batra V.K., Beard W.A., Shock D.D., Krahn J.M., Pedersen L.C., and Wilson S.H. Magnesium-induced assembly of a complete DNA polymerase catalytic complex. Structure 14 (2006) 757-766
51. Rittinger K., Divita G., and Goody R.S. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc. Natl Acad. Sci. USA 92 (1995) 8046-8049
52. Spence R.A., Kati W.M., Anderson K.S., and Johnson K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267 (1995) 988-993
53. Pata J.D., Stirtan W.G., Goldstein S.W., and Steitz T.A. Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. Proc. Natl Acad. Sci. USA 101 (2004) 10548-10553
54. Himmel D.M., Das K., Clark Jr. A.D., Hughes S.H., Benjahad A., Oumouch S., et al. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. J. Med. Chem. 48 (2005) 7582-7591
55. Esnouf R., Ren J., Ross C., Jones Y., Stammers D., and Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Struct. Biol. 2 (1995) 303-308
56. Tantillo C., Ding J., Jacobo-Molina A., Nanni R.G., Boyer P.L., Hughes S.H., et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 243 (1994) 369-387
57. Arnold E., Jacobo-Molina A., Nanni R.G., Williams R.L., Lu X., Ding J., et al. Structure of HIV-1 reverse transcriptase/DNA complex at 7 Å resolution showing active site locations. Nature 357 (1992) 85-89
58. Clark A.D.J., Jacobo-Molina A., Clark P., Hughes S.H., and Arnold E. Crystallization of human immunodeficiency virus type 1 reverse transcriptase with and without nucleic acid substrates, inhibitors and an antibody Fab fragment. Methods Enzymol. 262 (1995) 171-185
59. Otwinowski Z., and Minor W. DENZO and SCALEPACK. In: Rossmann M.G., and Arnold E. (Eds). International Tables for Crystallography: F, Crystallography of Biological Macromolecules (2001), Kluwer Academic Publishers, Boston
60. Jones T.A., Zou J.Y., Cowan S.W., and Kjeldgaard. Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallog. sect. A 47 (1991) 110-119
61. Brunger A.T., Adams P.D., and Rice L.M. Recent developments for the efficient crystallographic refinement of macromolecular structures. Curr. Opin. Struct. Biol. 8 (1998) 606-611
62. Nicholls A., Sharp K.A., and Honig B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins: Struct. Funct. Genet. 11 (1991) 281-296